Chromatin regulators mediate anthracycline sensitivity in breast cancer.

ABSTRACT: Anthracyclines are a highly effective component of curative breast cancer chemotherapy but are associated with substantial morbidity^1,2. Because anthracyclines work in part by inhibiting topoisomerase-II (TOP2) on accessible DNA^3,4, we hypothesized that chromatin regulatory genes (CRGs) that mediate DNA accessibility might predict anthracycline response. We studied the role of CRGs in anthracycline sensitivity in breast cancer through integrative analysis of patient and cell line data. We identified a consensus set of 38 CRGs associated with anthracycline response across ten cell line datasets. By evaluating the interaction between expression and treatment in predicting survival in a metacohort of 1006 patients with early-stage breast cancer, we identified 54 CRGs who

SUBMITTER: Seoane JA 

PROVIDER: S-EPMC7220800 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature